Figure 3.

Cadonilimab demonstrates preferential higher avidity binding to higher density of PD-1 and CTLA-4. In a Fortebio assay, cadonilimab showed higher binding avidity with a (a) high density of PD-1 and CTLA-4, where PD-1 (50 nM) and CTLA-4 (50 nM) were loaded onto the sensor, compared with (b) that of a relative low density of PD-1, where PD-1 (10 nM) was loaded onto the sensor. Penpulimab (parental PD-1 antibody of cadonilimab) showed similar binding avidity under these antigen conditions (a) and (b).